Ramin Madani - Department of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Mohammad Mahdi Heidari - Department of Biostatistics, Kashan University of Medical Sciences, Isfahan, Iran
Mohammad Ali Sabahi - Department of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Mahdi Salehi - Student Research Committee, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Davood Kheirkhah - Department of Pediatrics, School of Medicine, Infectious Diseases Research Center, Shahid Beheshti Hospital, Kashan University of Medical Sciences
Abbas Taghavi-Ardakani - Associated professor, Pediatric Department, Kashan University of Medical Sciences, Isfahan, Iran.
Somayeh Jamei - Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Amir Mahdi Shafiei - Student Research Committee, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Hamid Reza Gilasi - Department of Biostatistics and Epidemiology, Kashan University of Medical Sciences, Kashan, Iran.

Background: Gastroesophageal Reflux Disease (GERD) is common in infants and its treatment remains extremely challenging in this age group. Therefore this study aimed to compare the efficacy and safety of omeprazole and esomeprazole in infants, aged ۱-۱۱ months old, presented with GERD. Methods: This double-blind randomized controlled trial was conducted on ۸۰ infants. All patients were randomly divided into omeprazole and esomeprazole treatment groups for four weeks. The signs, symptoms, and disease severity based on the Visual Analog Scale (VAS) of GERD were evaluated after treatment in both groups. The data were then analyzed using the SPSS Statistics software (version ۲۱). Results: The results of this study did not show significant differences between the mean disease severity based on VAS of both omeprazole- (۸۱.۱±۵۵.۷) and esomeprazole-receiving (۷۹.۱±۷۷.۶) groups (p=۰.۰۹۱). However, in each group, the mean disease severity after one month of treatment was significantly lower as compared to baseline (p<۰.۰۱). The recovery rates were similar in both groups (۷۵% and ۷۰% for omeprazole and esomeprazole groups, respectively) (p=۰.۷۹۹). Conclusion: Omeprazole and esomeprazole did not have significant differences in signs, symptoms, and disease severity of GERD, however, we observed a significant reduction in disease severity in both groups indicating that these two drugs could be used interchangeably for the treatment of GERD disorder.

Comparative Research,,, ,،Gastroesophageal Reflux Disease,,, ,،GERD,,, ,،Omeprazole,,, ,،Esomeprazole,,, ,،Infants